Information  X 
Enter a valid email address

Proteome Sciences (PRM)

  Print      Mail a friend

Friday 24 February, 2012

Proteome Sciences

Director/PDMR Shareholding

RNS Number : 1173Y
Proteome Sciences PLC
24 February 2012

Proteome Sciences plc


Grants under the LTIP


Proteome Sciences plc ("Proteome") announces that on 24 February 2012 it made an award of options over 328,105 Ordinary Shares of 1 pence each with an exercise price of 1 pence per share to Christopher Pearce, Chief Executive Officer under the 2011 Long Term Incentive Plan (the "LTIP")  . 


This brings the total number of shares subject to awards and options now held by Mr Pearce to 1,779,448.


This notification is made in accordance with Rule 17 of the AIM Rules. 




For further information please contact:


Proteome Sciences plc

Tel: +44 (0)1932 865065

Christopher Pearce, Chief Executive Officer

James Malthouse, Finance Director

Dr. Ian Pike, Chief Operating Officer

Nominated Adviser

Singer Capital Markets Limited

Tel: +44 (0)20 3205 7500

Shaun Dobson/Claes Spång

Public Relations

FTI Consulting

IKON Associates

Ben Atwell/Mo Noonan

Adrian Shaw

Tel:       +44 (0)20 7269 7116

Tel:       +44 (0)1483 271291


Mobile:  +44 (0)7979 900733



Notes to Editors:


About Proteome Sciences

Proteome Sciences is a global leader in applied proteomics and peptidomics offering high sensitivity, proprietary technologies for protein and peptide biomarker discovery, validation and assay development.


Its PS Biomarker Services™ uses isobaric and isotopic Tandem Mass Tag® (TMT®) workflows developed on the latest Orbitrap Velos and TSQ Vantage mass spectrometers to deliver rapid, robust and reproducible biomarker assay development for customers in the pharmaceutical, diagnostic and biotechnology sectors. Services are provided from its ISO 9001: 2008 accredited facilities in Frankfurt, Germany. By combining Selected Reaction Monitoring (SRM) and TMT workflows highly multiplexed assays can be developed rapidly and are suitable for screening hundreds of candidate biomarkers in larger validation studies and can be transferred for immunoassay development. The Company's own research has discovered a large number of novel protein biomarkers in key human diseases and is focused mainly in neurological/neurodegenerative conditions and in cancer. It has discovered and patented blood biomarkers, including Alzheimer's disease, stroke, brain damage and lung cancer for diagnostic and treatment applications that are available for license or are already outlicensed. Proteome Sciences, based in Cobham, UK, with facilities in London and Frankfurt, delivers outsourced proteomics services and proprietary biomarkers/biomarker assays to pharmaceutical, biotechnology and diagnostics companies.



This information is provided by RNS
The company news service from the London Stock Exchange